Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Xceleron and Kinetigen Announce Partnership

Published: Friday, March 01, 2013
Last Updated: Friday, March 01, 2013
Bookmark and Share
Partnership to simplify and empower Phase I clinical investigations.

Xceleron has announced a partnership with Kinetigen, a clinical pharmacology consulting firm specializing in pharmacokinetics.

The partnership will offer drug developers simpler and more robust early clinical investigations.

Non-optimized or incomplete pharmacokinetic analyses commonly result in additional expenses and lost time over the course of a development program; such problems frequently become evident during expensive proof-of-concept investigations.

Thoroughly understanding the pharmacokinetics of a drug or biologic in clinical Phase I studies allows investigators to make decisions earlier.

Phase I pharmacokinetic investigations must be properly designed to ensure that their results will translate into proof-of-concept and must be conducted in a cost-effective manner.

The partnership between Xceleron and Kinetigen is ideally suited to provide powerful and cost-effective investigations of Phase I drug pharmacokinetics. Kinetigen specializes in complex pharmacokinetic analyses and overall clinical pharmacology strategy.

Xceleron uses Accelerator Mass Spectrometry (AMS) to gain analytical insight across a broad range of asset classes and matrix types.

Together, Xceleron and Kinetigen leverage a conventional Phase I approach to expand the knowledge base and value of intellectual property before the onset of expensive late-phase clinical investigations.

“At Xceleron, we believe that technology can get life-changing drugs to people who need them, sooner and at a lower cost. This partnership with Kinetigen will help our clients do that by efficiently and cost-effectively answering critical questions earlier,” said Dr. Michael Butler, CEO of Xceleron.

“Our partnership with Xceleron is very synergistic,” said Dr. Geoffrey Banks, CEO of Kinetigen. “Matching Kinetigen’s pharmacokinetic expertise with Xceleron’s AMS technology is a ‘win-win’ situation for clients seeking more robust options for analysis and interpretation of Phase 1 PK data.”

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Xceleron and JCL Bioassay Announce Partnership in Early Clinical Investigations
New offering will expand access to powerful analytical platforms.
Tuesday, March 19, 2013
Xceleron Announces New Investment and Move to Purpose-Built Laboratories in U.S.
Demand in translational science drives need for additional equipment.
Tuesday, February 07, 2012
Xceleron Announces Key Board and Executive Appointments
Increasing demand from big pharma for greater R&D productivity.
Thursday, July 21, 2011
Scientific News
Salford Lung Study - The First Real World Clinical Trial
In this podcast, we learn about the Salford Lung Study and its potential to revolutionize the way we assess new drugs and treatments around the world.
NIH Contributes to Global Effort to Prevent and Manage Lung Diseases
The large scale trial will measure health benefits of clean cookstoves.
Anti-Inflammatory Drugs Could Help Treat Depression
Anti-inflammatory drugs could be used to treat some cases of depression, which further implicates our immune system in mental health disorders.
Questioning the Safety of Selenium to Combat Cancer
Research indicates the need for change in practice as selenium supplements cannot be recommended for preventing colorectal cancer.
Scientists at NIH and Emory Achieve Sustained SIV Remission in Monkeys
The finding suggest that the immune systems of these animals are controlling SIV replication in the absence of antiretroviral therapy.
Painting the Way to Tumour Imaging
Tumour paint used in emergency surgery to aid cell identification for surgeons.
Anti-Cancer Drug Uses Tumour mRNA to Identify Responders
Phase I study of novel anti-cancer drug uses tumour mRNA expression to identify patients who will respond to the drug.
Targeting Estrogen Receptor Improves Survival in Breast Cancer
Trial finds estrogen receptor degrader significantly increases progression-free survival in patients with advanced breast cancer.
Clinical Trial Finds Medicine Program Alters Blood Serum
Meditation, yoga and vegetarian diet linked to decline in plasma metabolites associated with inflammation and cardiovascular disease risk.
Alzheimer’s Linked Protein Can Be Removed From Brain Without Hindering Memory, Learning
Researchers at UTSW have found that the mice can maintain their learning and memory when virtually all ApoE is removed from the brain but kept present in the liver to filter cholesterol.
Scroll Up
Scroll Down

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos